Gilead Moves To Block Harvoni Infringer In India
This article was originally published in Scrip
Executive Summary
Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals.
You may also be interested in...
Cadila-Hetero Slugfest Over The 'Hep' Tag
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet